metoprolol has been researched along with Atrial Remodeling in 1 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Atrial Remodeling: Long-term changes in the electrophysiological parameters and/or anatomical structures of the HEART ATRIA that result from prolonged changes in atrial rate, often associated with ATRIAL FIBRILLATION or long periods of intense EXERCISE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we investigated the roles of metoprolol in regulation of atrial remodeling induced by chronic OSA." | 7.85 | Metoprolol prevents chronic obstructive sleep apnea-induced atrial fibrillation by inhibiting structural, sympathetic nervous and metabolic remodeling of the atria. ( Dong, X; Li, H; Li, M; Li, Y; Lu, S; Sun, L; Wang, X; Wang, Y; Yan, S; Yu, S; Zhao, J; Zhao, S, 2017) |
| " Here, we investigated the roles of metoprolol in regulation of atrial remodeling induced by chronic OSA." | 3.85 | Metoprolol prevents chronic obstructive sleep apnea-induced atrial fibrillation by inhibiting structural, sympathetic nervous and metabolic remodeling of the atria. ( Dong, X; Li, H; Li, M; Li, Y; Lu, S; Sun, L; Wang, X; Wang, Y; Yan, S; Yu, S; Zhao, J; Zhao, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, L | 1 |
| Yan, S | 1 |
| Wang, X | 1 |
| Zhao, S | 1 |
| Li, H | 1 |
| Wang, Y | 1 |
| Lu, S | 1 |
| Dong, X | 1 |
| Zhao, J | 1 |
| Yu, S | 1 |
| Li, M | 1 |
| Li, Y | 1 |
1 other study available for metoprolol and Atrial Remodeling
| Article | Year |
|---|---|
Metoprolol prevents chronic obstructive sleep apnea-induced atrial fibrillation by inhibiting structural, sympathetic nervous and metabolic remodeling of the atria.
Topics: Adrenergic beta-1 Receptor Antagonists; AMP-Activated Protein Kinase Kinases; Animals; Atrial Fibril | 2017 |